Federal Circuit Affirms Ruling Against AlexSam in Multifunction Card Patent Dispute with Cigna
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | AlexSam, Inc. v. CIGNA Corp. |
| Case Number | 22-1599 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District Court |
| Duration | Apr 2022 – Apr 2024 2 years 0 months |
| Outcome | Plaintiff Loss — No Infringement |
| Patents at Issue | |
| Accused Products | Cigna Multifunction Card Systems |
Case Overview
The Parties
⚖️ Plaintiff
Texas-based patent assertion entity with an extensive portfolio of patents covering multifunction card technologies.
🛡️ Defendant
One of the largest managed healthcare and insurance organizations in the United States, with technology infrastructure supporting member benefits and payment processing.
The Patent at Issue
This case centered on claims 32 and 33 of **U.S. Patent No. 6,000,608**, covering a multifunction card system. The patent has broad commercial relevance across healthcare payment and benefits administration technologies.
- • US 6,000,608 — Multifunction card system enabling multiple transactional functions.
- • The broader case record also referenced additional patents in AlexSam’s portfolio, including U.S. Patent Nos. 5,557,517; 5,477,038; 5,557,516; 5,621,201; 5,704,046.
Developing card-based payment systems?
Check if your technology might infringe existing patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a clear ruling: **AFFIRMED**. AlexSam’s appeal was dismissed, and the district court’s finding — that AlexSam failed to provide sufficient evidence of Cigna’s infringement of claims 32 and 33 of the ‘608 patent — was upheld. No damages were awarded to AlexSam, and the record reflects no injunctive relief.
Key Legal Issues
The Federal Circuit’s analysis focused on **evidentiary sufficiency** in establishing patent infringement. The court found that AlexSam did not present adequate proof that Cigna’s multifunction card systems practiced each limitation of claims 32 and 33. This outcome highlights the critical necessity of **claim-by-claim, element-by-element infringement analysis**. The Federal Circuit’s characterization of AlexSam’s arguments as “unpersuasive” underscores that appellate panels rigorously scrutinize evidentiary deficiencies.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in multifunction card and payment technologies. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View AlexSam’s portfolio in the multifunction card space
- Analyze related patents in healthcare payment tech
- Understand claim construction patterns for similar patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Integrated multifunction card systems
50+ Related Patents
In multifunction card tech space
Design-Around Options
Available for many claims
✅ Key Takeaways
Evidentiary sufficiency—not just patent validity—is a decisive battleground at the Federal Circuit.
Search related case law →Claim-specific, element-by-element infringement mapping is non-negotiable for surviving appellate review.
Explore precedents →Frequently Asked Questions
The appeal focused on claims 32 and 33 of U.S. Patent No. 6,000,608, a multifunction card system patent. The broader case involved a portfolio of AlexSam patents including U.S. Patent Nos. 5,557,517; 5,477,038; 5,704,046; and others.
The court found AlexSam failed to provide sufficient evidence that Cigna’s products infringed claims 32 and 33 of the ‘608 patent, affirming the district court’s ruling in its entirety.
The ruling reinforces rigorous evidentiary standards for infringement claims in card-based technology cases, potentially strengthening defendants’ positions in similar patent assertion entity (PAE) disputes.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 22-1599
- USPTO Patent Full-Text Database — U.S. Patent No. 6,000,608
- United States Court of Appeals for the Federal Circuit
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.